

Pharmacy Program Quarterly Update: Changes Effective Jan. 1, 2024 – Part 2

Contents

Pharmacy Benefit Reminders

Drug List Changes

Drug List Additions – Effective Jan. 1, 2024

Balanced Drug List Additions

Performance Drug List Additions

Performance Select Drug List Additions

Basic and Enhanced Drug List Additions

Basic Multi-Tier and Enhanced Multi-Tier Drug List Additions

Other Drug List Additions

Balanced Drug List Additions

Performance Drug List Additions

Performance Select Drug List Additions

Basic and Enhanced Additions, Basic Multi-Tier and Enhanced Multi-Tier Additions

Drug Tier Changes – Effective Jan. 1, 2024

Balanced Drug List Tier Changes

Performance Drug List Tier Changes

Performance Select Drug List Tier Changes

Other Drug List Tier Changes

Balanced Drug List Tier Changes

Performance Drug List Tier Changes

Performance Select Drug List Tier Changes

Utilization Management Program Changes

Dispensing Limit Changes

Balanced, Performance, and Performance Select, Basic, Basic Multi-Tier, Basic Annual, Basic Multi-Tier Annual, Enhanced, Enhanced Annual, Enhanced Annual Multi-Tier, Health Information Marketplace (HIM) Drug Lists

Standard Utilization Management Program Updates

Change in Benefit Coverage for Select High-Cost Products

Pharmacy Benefits Updates

BCBSMT Offers LifeScan as Preferred Option for Glucose Management

Appropriate Use of Opioids Program to be Retired January 2024

Reminder: BCBSMT's Updated Approach to Managing GLP-1 Agonist Medications

Reminder: The Quarterly Pharmacy Changes awareness article is published in two parts. This article is a continuation of the previously published January Quarterly Pharmacy Changes Part 1 article, which included changes that require member notification — drug list revisions/exclusions, dispensing limits, utilization management changes and general information on pharmacy benefit program updates. This Part 2 article contains recent coverage additions, utilization management updates and any other pharmacy program updates.

Pharmacy Benefit Reminders

A new year often welcomes new members to Blue Cross and Blue Shield of Montana or updates to benefits for our current members. Discussing your patient's pharmacy benefits can help with this transition.

As you visit with your patients, also consider the following:

- Your patient's pharmacy benefits may be new to them or apply to an updated drug list. The drug lists are available on our member and provider websites to help both you and your patients when prescribing medication.
- Review the prescription drug list before prescribing medications. Some drugs may have been excluded from coverage or have updated requirements applied to their utilization management program.
- If your patients need a coverage exception or prior authorization request, visit the Prior Authorization/Step Therapy Programs site for both forms and more information.
- Some members' plans may experience changes to the pharmacy network, such as moving to a new pharmacy
 network or changes to pharmacies participating within the network. Those impacted members received letters
 alerting of them of these potential out-of-pocket changes.

In most cases, no action is required on your part for these pharmacy network changes. Members can easily transfer prescriptions to an in-network pharmacy. You may want to ask which pharmacy is their preferred choice if your office stores pharmacy information on patient records.

• If you or your patients are concerned about a particular drug benefit change, call the number on their ID card to confirm any new or updated pharmacy benefits.

Treatment decisions are always between you and your patients. Coverage is subject to the terms and limits of your patients' benefit plans. Please advise them to review their benefit materials for details.

Drug List Changes

Based on the availability of new prescription medications and Prime's National Pharmacy and Therapeutics Committee's review of changes in the pharmaceuticals market, some additions (new to coverage) and/or some coverage tier changes (drugs moved to a lower out-of-pocket payment level) will be made to the Blue Cross and Blue Shield of Montana (BCBSMT) drug lists. Additions effective January 1, 2024, and previous updates are outlined below.

Please note: Revisions (drugs still covered but moved to a higher, out-of-pocket payment level) and/or exclusions (drugs no longer covered) are included in the January Quarterly Pharmacy Changes Part 1 article. Your patient(s) may ask you about therapeutic or lower cost alternatives if their medication is affected by one of these changes].

You can view the January drug lists on our member website.

Drug List Additions – Effective Jan. 1, 2024

| Drug ¹ | Condition |
|---|---|
| breyna (budesonide-formoterol dihydrate aero 80- 4.5 mcg/act,160-4.5 mcg/act) | Asthma, Chronic Obstructive Pulmonary Disease (COPD) |
| budesonide-formoterol dihydrate aero 80-4.5 mcg/act, 160- 4.5 mcg/act | Asthma, Chronic Obstructive Pulmonary Disease (COPD) |
| CARBINOXAMINE MALEATE (carbinoxamine maleate soln 4 mg/5 ml) | Allergic Symptoms, Allergic Reactions |
| CUVRIOR (trientine tetrahydrochloride tab 300 mg) | Wilson disease |
| fluticasone-salmeterol aer powder ba 100-50 mcg/act, 250- 50 mcg/act, 500-50 mcg/act | Asthma, Chronic Obstructive Pulmonary Disease (COPD) |
| MEKINIST (trametinib dimethyl sulfoxide for soln 0.05 mg/ml (base eq)) | Cancer |
| ONETOUCH ULTRA (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA BLUE (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA CONTROL (blood glucose calibration - liquid) | Diabetes |
| ONETOUCH ULTRA TEST STRIPS (glucose blood test strip) | Diabetes |
| ONETOUCH VERIO CONTROL SOLUTION HIGH (blood glucose calibration - liquid - high) | Diabetes |
| ONETOUCH VERIO IN VITRO MEDI-CAL (glucose blood test strip) | Diabetes |
| ONETOUCH VERIO MID CONTROL SOLUTION (blood glucose calibration - liquid) | Diabetes |
| ONETOUCH VERIO TEST STRIPS (glucose blood test strip) | Diabetes |
| TAFINLAR (dabrafenib mesylate tab for oral susp 10 mg (base equiv)) | Cancer |

Balanced Drug List Additions

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Balanced Drug List Additions

| Drug ¹ | Condition |
|--|------------------------|
| TEZSPIRE (tezepelumab-ekko subcutaneous soln auto-inj 210 mg/1.91 ml) | Asthma |
| VOWST (fecal microbiota spores, live-brpk caps) | C. difficile infection |
| ZOLPIDEM TARTRATE (zolpidem tartrate cap 7.5 mg) | Insomnia |

Performance Drug List Additions

| Drug ¹ | Condition |
|--|---|
| AUVI-Q (epinephrine solution auto-injector 0.1 mg/0.1 ml, 0.15 mg/0.15 ml (1:1000), 0.3 mg/0.3 ml (1:1000)) | Anaphylaxis, Severe Hypersensitivity Reactions |
| fluticasone-salmeterol aer powder ba 100-50 mcg/act, 250- 50 mcg/act, 500-50 mcg/act | Asthma, Chronic Obstructive Pulmonary Disease (COPD) |
| MEKINIST (trametinib dimethyl sulfoxide for soln 0.05 mg/ml (base eq)) | Cancer |
| ONETOUCH ULTRA (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA BLUE (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA CONTROL (blood glucose calibration - liquid) | Diabetes |
| ONETOUCH ULTRA TEST STRIPS (glucose blood test strip) | Diabetes |
| ONETOUCH VERIO CONTROL SOLUTION HIGH (blood glucose calibration - liquid - high) | Diabetes |
| ONETOUCH VERIO IN VITRO MEDI-CAL (glucose blood test strip) | Diabetes |
| ONETOUCH VERIO MID CONTROL SOLUTION (blood glucose calibration - liquid) | Diabetes |
| ONETOUCH VERIO TEST STRIPS (glucose blood test strip) | Diabetes |
| TAFINLAR (dabrafenib mesylate tab for oral susp 10 mg (base equiv)) | Cancer |
| TEZSPIRE (tezepelumab-ekko subcutaneous soln auto-inj 210 mg/1.91 ml) | Asthma |
| VOWST (fecal microbiota spores, live-brpk caps) | C. difficile infection |

Performance Select Drug List Additions

| Drug | Condition |
|---|---|
| breyna (budesonide-formoterol dihydrate aero 80-4.5 mcg/act, 160-4.5 mcg/act) | Asthma, Chronic Obstructive Pulmonary Disease (COPD) |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Performance Select Drug List Additions

| Drug | Condition |
|--|---|
| budesonide-formoterol dihydrate aero 80-4.5 mcg/act, 160-4.5 mcg/act | Asthma, Chronic Obstructive Pulmonary Disease (COPD) |
| fluticasone-salmeterol aer powder ba 100-50 mcg/act, 250-50 mcg/act, 500-50 mcg/act | Asthma, Chronic Obstructive Pulmonary Disease (COPD) |
| HEMANGEOL (propranolol hcl oral soln 4.28 mg/ml) | Infantile Hemangioma |
| MEKINIST (trametinib dimethyl sulfoxide for soln 0.05 mg/ml (base eq)) | Cancer |
| ONETOUCH ULTRA (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA BLUE (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA CONTROL (blood glucose calibration - liquid) | Diabetes |
| ONETOUCH ULTRA TEST STRIPS (glucose blood test strip) | Diabetes |
| ONETOUCH VERIO CONTROL SOLUTION HIGH (blood glucose calibration - liquid - high) | Diabetes |
| ONETOUCH VERIO IN VITRO MEDI-CAL (glucose blood test strip) | Diabetes |
| ONETOUCH VERIO MID CONTROL SOLUTION (blood glucose calibration - liquid) | Diabetes |
| ONETOUCH VERIO TEST STRIPS (glucose blood test strip) | Diabetes |
| TAFINLAR (dabrafenib mesylate tab for oral susp 10 mg (base equiv)) | Cancer |
| TEZSPIRE (tezepelumab-ekko subcutaneous soln auto-inj 210 mg/1.91 ml) | Asthma |
| VOWST (fecal microbiota spores, live-brpk caps) | C. <i>difficile</i> infection |

Basic and Enhanced Drug List Additions

| Drug ¹ | Condition |
|---|--|
| AUVI-Q (epinephrine solution auto-injector 0.1 mg/0.1 ml, 0.15 mg/0.15 ml, 0.15 mg/0.15 ml, 0.3 mg/0.3 ml | Anaphylaxis, Severe Hypersensitivity Reactions |
| LO LOESTRIN FE (norethin-eth estradiol-fe tab 1 mg-10 mcg (24)/10 mcg (2)) | Contraception |
| MEKINIST (trametinib dimethyl sulfoxide for soln 0.05 mg/ml (base eq)) | Cancer |
| ONETOUCH ULTRA (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA BLUE (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA TEST STRIPS (glucose blood test strip) | Diabetes |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Basic and Enhanced Drug List Additions

| Drug ¹ | Condition |
|--|-----------|
| ONETOUCH VERIO IN VITRO MEDICAL (glucose blood test strip) | Diabetes |
| ONETOUCH VERIO TEST STRIPS (glucose blood test strip) | Diabetes |
| TAFINLAR (dabrafenib mesylate tab for oral susp 10 mg (base equiv)) | Cancer |
| TEZSPIRE (tezepelumab-ekko subcutaneous soln auto-inj 210 mg/1.91 ml) | Asthma |

Basic Multi-Tier and Enhanced Multi-Tier Drug List Additions

| Drug ¹ | Condition |
|--|---|
| amitriptyline hcl tab 75 mg | Depression |
| amoxicillin & k clavulanate for susp 400-57 mg/5 ml | Infections |
| amphetamine-dextroamphetamine tab 5 mg | ADHD, Narcolepsy/Daytime Sleepiness |
| armodafinil tab 50 mg | Sleep Disorders |
| AUVI-Q (epinephrine solution auto-injector 0.1 mg/0.1 ml, 0.15 mg/0.15 ml, 0.15 ml, 0.15 ml, 0.3 mg/0.3 ml | Anaphylaxis, Severe Hypersensitivity Reactions |
| azithromycin for susp 200 mg/5 ml | Infections |
| baclofen tab 20 mg | Spasticity associated with Multiple Sclerosis and Spinal Cord Lesions |
| bisoprolol & hydrochlorothiazide tab 10-6.25 mg, 2.5-6.25 mg | Hypertension |
| bumetanide tab 0.5 mg | Edema, Volume Overload |
| bupropion hcl tab 100 mg | Depression |
| cefuroxime axetil tab 250 mg | Infections |
| cephalexin for susp 125 mg/5 ml | Infections |
| choline fenofibrate cap dr 45 mg (fenofibric acid equiv) | Hypertriglyceridemia |
| cimetidine tab 200 mg | Heartburn |
| clotrimazole w/ betamethasone cream 1-0.05% | Fungal Infections |
| clozapine tab 25 mg | Schizophrenia, suicidal behavior in schizophrenia |
| cyproheptadine hcl syrup 2 mg/5 ml | Allergic Symptoms, Allergic Reactions |
| desloratadine tab 5 mg | Allergic Rhinitis, Urticaria |
| desogest-eth estrad & eth estrad tab 0.15-0.02/0.01 mg (21/5) | Contraception |
| diazepam oral soln 1 mg/ml | Alcohol withdrawal syndrome, anxiety, muscle spasm, spasticity, or rigidity, seizures |
| diltiazem hcl cap er 24 hr 120 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Basic Multi-Tier and Enhanced Multi-Tier Drug List Additions

| Drug ¹ | Condition |
|--|--|
| diltiazem hcl coated beads cap er 24 hr 240 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina |
| diphenhydramine hcl elixir 12.5 mg/5 ml | Allergic symptoms, adjunct in treatment of anaphylaxis, insomnia |
| doxepin hcl cap 25 mg | Depression |
| doxycycline hyclate tab 20 mg | Acne, Infections |
| doxycycline monohydrate tab 50 mg | Acne, Infections |
| drospirenone-ethinyl estradiol tab 3-0.03 mg | Contraception |
| esomeprazole magnesium cap delayed release 20 mg (base eq) | Gastroesophageal Reflux Disease, H. pylori eradication, pathological hypersecretory conditions, risk reduction of NSAID-associated gastric ulcer |
| flurbiprofen tab 100 mg | Osteoarthritis, Rheumatoid Arthritis |
| fluticasone propionate cream 0.05% | Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses |
| guanfacine hcl tab er 24 hr 1 mg, 2 mg, 3 mg, 4 mg (base equiv) | ADHD |
| hydrocodone bitart-homatropine methylbrom soln 5-1.5 mg/5 ml | Cough |
| hydrocodone w/ homatropine syrup 5-1.5 mg/5 ml | Cough |
| hydrocodone-acetaminophen tab 10-325 mg | Pain |
| hydrocortisone lotion 2.5% | Pruritus, Dermatoses |
| ketorolac tromethamine tab 10 mg | Pain |
| lactulose (encephalopathy) solution 10 gm/15 ml | Hepatic Encephalopathy |
| lidocaine oint 5% | Local anesthetic |
| LO LOESTRIN FE (norethin-eth estradiol-fe tab 1 mg-10 mcg (24)/10 mcg (2)) | Contraception |
| mafenide acetate packet for topical soln 5% (50 gm) | Burns |
| medroxyprogesterone acetate im susp prefilled syr 150 mg/ml | Contraception |
| MEKINIST (trametinib dimethyl sulfoxide for soln 0.05 mg/ml (base eq)) | Cancer |
| methotrexate sodium tab 2.5 mg (base equiv) | Cancer, Rheumatoid Arthritis, Psoriasis, Polyarticular Juvenile Arthritis |
| methylphenidate hcl tab 10 mg | ADHD, Narcolepsy |
| nitrofurantoin monohydrate macrocrystalline cap 100 mg | Cystitis |
| norgestrel & ethinyl estradiol tab 0.3 mg-30 mcg | Contraception |
| nystatin susp 100,000 unit/ml | Oral Candidiasis |
| olmesartan medoxomil-hydrochlorothiazide tab 40-12.5 mg, 40-25 mg | Hypertension |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Basic Multi-Tier and Enhanced Multi-Tier Drug List Additions

| Drug ¹ | Condition |
|--|---|
| ondansetron hcl oral soln 4 mg/5 ml | Nausea and Vomiting |
| ONETOUCH ULTRA (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA BLUE (glucose blood test strip) | Diabetes |
| ONETOUCH ULTRA TEST STRIPS (glucose blood test strip) | Diabetes |
| ONETOUCH VERIO IN VITRO MEDICAL (glucose blood test strip) | Diabetes |
| ONETOUCH VERIO TEST STRIPS (glucose blood test strip) | Diabetes |
| oxcarbazepine tab 150 mg | Seizures |
| potassium phosphate monobasic tab 500 mg | To acidify the urine to lower urinary calcium; reduce odor and rash caused by ammonia in urine; to increase antibacterial activity of methenamine |
| prednisone tab therapy pack 10 mg (21) | Inflammatory Conditions |
| propranolol hcl oral soln 20 mg/5 ml | Angina, atrial fibrillation, essential tremor, hypertension, migraine, myocardial infarction, pheochromocytoma, hypertrophic subaortic stenosis |
| pseudoephed-bromphen-dm syrup 30-2-10 mg/5 ml | Upper respiratory tract conditions |
| quetiapine fumarate tab er 24 hr 150 mg | Bipolar disorder, depression, schizophrenia |
| rabeprazole sodium ec tab 20 mg | Gastroesophageal Reflux Disease, H. pylori eradication, pathological hypersecretory conditions, peptic ulcer disease |
| rizatriptan benzoate oral disintegrating tab 5 mg, 10 mg (base eq) | Migraine |
| solifenacin succinate tab 10 mg | Overactive Bladder |
| TAFINLAR (dabrafenib mesylate tab for oral susp 10 mg (base equiv)) | Cancer |
| tamoxifen citrate tab 20 mg (base equivalent) | Breast cancer (treatment and risk reduction) |
| telmisartan tab 20 mg | Hypertension, cardiovascular risk reduction |
| testosterone cypionate im inj in oil 100 mg/ml | Primary hypogonadism, hypogonadotropic hypogonadism |
| TEZSPIRE (tezepelumab-ekko subcutaneous soln auto-inj 210 mg/1.91 ml) | Asthma |
| tizanidine hcl cap 2 mg (base equivalent) | Spasticity |
| triazolam tab 0.125 mg | Insomnia |
| valsartan tab 320 mg | Heart failure, Hypertension, Cardiovascular risk reduction post-myocardial infarction |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Other Drug List Additions

Most additions to the drug list become effective quarterly, however, some drugs are added as part of formulary maintenance (e.g., new strength of covered drug) or re-evaluated during the quarter then added to the list. Those drugs are listed below.

| Drug ¹ | Condition | Date Added |
|--|--|------------|
| ALTUVIIIO (antihemophilic fact rcmb fc-vwf-xten-ehtl for inj 750 unit) | Hemophilia A | 11/5/2023 |
| BACLOFEN (baclofen oral soln 5 mg/5 ml) | Spasticity associated with Multiple Sclerosis and Spinal Cord Lesions | 10/22/2023 |
| BREO ELLIPTA (fluticasone furoate-vilanterol aero powd ba 50-25 mcg/act) | Asthma, Chronic Obstructive Pulmonary Disease (COPD) | 12/1/2023 |
| FASTEP COVID-19 ANTIGEN HOME TEST (covid-19 at home antigen test kit)* | COVID-19 Test | 10/15/2023 |
| GLIPIZIDE (glipizide tab 2.5 mg) | Diabetes | 10/22/2023 |
| GOTOKNOW COVID-19 ANTIGEN RAPID TEST (covid- 19 at home antigen test kit)* | COVID-19 Test | 10/8/2023 |
| JOENJA (leniolisib phosphate tab 70 mg) | Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) | 11/1/2023 |
| LAGEVRIO (molnupiravir cap 200 mg) | COVID-19 | 11/5/2023 |
| LUPRON DEPOT-PED (leuprolide acet (6 month) for im in j pediatric kit 45 mg) | Central Precocious Puberty | 12/1/2023 |
| NOVAVAX COVID-19 VACCINE/ 2023-24 (covid-19 subunit prot recom adjuv vac-novavax im 5 mcg/0.5 ml) | COVID-19 Vaccine | 10/3/2023 |
| OMNITROPE (somatropin for inj 5.8 mg) | Growth Hormone Deficiency, Short Stature, Growth Failure | 11/15/2023 |
| OMNITROPE (somatropin solution cartridge 5 mg/1.5 ml, 10 mg/1.5 ml) | Growth Hormone Deficiency, Short Stature, Growth Failure | 11/15/2023 |
| OPVEE (nalmefene hcl nasal spray 2.7 mg/0.1 ml (base equiv)) | Opioid Overdose | 12/1/2023 |
| OSPHENA (ospemifene tab 60 mg) | Dyspareunia, Vaginal Dryness | 10/8/2023 |
| PAXLOVID (nirmatrelvir tab 10 x 150 mg & ritonavir tab 10 x 100 mg pak, 20 x 150 mg & ritonavir tab 10 x 100 mg pak) | COVID-19 | 10/22/2023 |
| pazopanib hcl tab 200 mg (base equiv) | Cancer | 10/22/2023 |
| pitavastatin calcium tab 1 mg, 2 mg, 4 mg | Hyperlipidemia, Hypercholesterolemia | 11/5/2023 |
| spironolactone susp 25 mg/5 ml | Heart Failure, Hypertension, Edema | 10/29/2023 |
| TRIENTINE HYDROCHLORIDE (trientine hcl cap 500 mg) | Wilson disease | 10/8/2023 |

Balanced Drug List Additions

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

^{*}Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Please note: If coverage of the member's medication is changed on their prescription drug list, the amount the member will pay for the same medication under this preventive drug benefit may also change.

Balanced Drug List Additions

| Drug ¹ | Condition | Date Added |
|---|------------------|------------|
| VITAMEDMD ONE RX/QUATREFO LIC (prenat w/o a w/fefum-methfol-fa-dha cap 30-0.6-0.4-200 mg) | Prenatal Vitamin | 10/8/2023 |

Performance Drug List Additions

| Drug ¹ | Condition | Date Added |
|---|--|------------|
| ALTUVIIIO (antihemophilic fact rcmb fc-vwf-xten-ehtl for inj 750 unit) | Hemophilia A | 11/5/2023 |
| BREO ELLIPTA (fluticasone furoate-vilanterol aero powd ba 50-25 mcg/act) | Asthma, Chronic Obstructive Pulmonary Disease (COPD) | 12/1/2023 |
| GLIPIZIDE (glipizide tab 2.5 mg) | Diabetes | 10/22/2023 |
| INSULIN GLARGINE-YFGN (insulin glargine-yfgn inj 100 unit/ml) | Diabetes | 10/22/2023 |
| JOENJA (leniolisib phosphate tab 70 mg) | Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) | 11/1/2023 |
| LAGEVRIO (molnupiravir cap 200 mg) | COVID-19 | 11/5/2023 |
| LUPRON DEPOT-PED (leuprolide acet (6 month) for im inj pediatric kit 45 mg) | Central Precocious Puberty | 12/1/2023 |
| NOVAVAX COVID-19 VACCINE/ 2023-24 (covid-19 subunit prot recom adjuv vac-novavax im 5 mcg/0.5 ml) | COVID-19 Vaccine | 10/3/2023 |
| OMNITROPE (somatropin for inj 5.8 mg) | Growth Hormone Deficiency, Short Stature, Growth Failure | 11/15/2023 |
| OMNITROPE (somatropin solution cartridge 5 mg/1.5 ml, 10 mg/1.5 ml) | Growth Hormone Deficiency, Short Stature, Growth Failure | 11/15/2023 |
| OPVEE (nalmefene hcl nasal spray 2.7 mg/0.1 ml (base equiv)) | Opioid Overdose | 12/1/2023 |
| PAXLOVID (nirmatrelvir tab 10 x 150 mg & ritonavir tab 10 x 100 mg pak) | COVID-19 | 10/22/2023 |
| PAXLOVID (nirmatrelvir tab 20 x 150 mg & ritonavir tab 10 x 100 mg pak) | COVID-19 | 10/22/2023 |
| pazopanib hcl tab 200 mg (base equiv) | Cancer | 10/22/2023 |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Performance Select Drug List Additions

| Drug ¹ | Condition | Date Added |
|--|--|------------|
| ALTUVIIIO (antihemophilic fact rcmb fc-vwf-xten-ehtl for inj 750 unit) | Hemophilia A | 11/5/2023 |
| BREO ELLIPTA (fluticasone furoate-vilanterol aero powd ba 50-25 mcg/act) | Asthma, Chronic Obstructive Pulmonary Disease (COPD) | 12/1/2023 |
| GLIPIZIDE (glipizide tab 2.5 mg) | Diabetes | 10/22/2023 |
| JOENJA (leniolisib phosphate tab 70 mg) | Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) | 11/1/2023 |
| LAGEVRIO (molnupiravir cap 200 mg) | COVID-19 | 11/5/2023 |
| LUPRON DEPOT-PED (leuprolide acet (6 month) for im inj pediatric kit 45 mg) | Central Precocious Puberty | 12/1/2023 |
| NOVAVAX COVID-19 VACCINE/ 2023-24 (covid-19 subunit prot recom adjuv vac-novavax im 5 mcg/0.5 ml) | COVID-19 Vaccine | 10/3/2023 |
| OMNITROPE (somatropin for inj 5.8 mg) | Growth Hormone Deficiency, Short Stature, Growth Failure | 11/15/2023 |
| OMNITROPE (somatropin solution cartridge 5 mg/1.5 ml, 10 mg/1.5 ml) | Growth Hormone Deficiency, Short Stature, Growth Failure | 11/15/2023 |
| OPVEE (nalmefene hcl nasal spray 2.7 mg/0.1 ml (base equiv)) | Opioid Overdose | 12/1/2023 |
| PAXLOVID (nirmatrelvir tab 10 x 150 mg & ritonavir tab 10 x 100 mg pak, 20 x 150 mg & ritonavir tab 10 x 100 mg pak) | COVID-19 | 10/22/2023 |
| pazopanib hcl tab 200 mg (base equiv) | Cancer | 10/22/2023 |
| pitavastatin calcium tab 1 mg, 2 mg, 4 mg | Hyperlipidemia, Hypercholesterolemia | 11/5/2023 |

Basic and Enhanced Additions, Basic Multi-Tier and Enhanced Multi-Tier Additions

| Drug ¹ | Condition | Date Added |
|--|---|------------|
| ALTUVIIIO (antihemophilic fact rcmb fc-vwf-xten-ehtl for inj 750 unit) | Hemophilia A | 11/5/2023 |
| OMNITROPE (somatropin for inj 5.8 mg) | Growth Hormone Deficiency, Short Stature, Growth Failure | 11/15/2023 |
| OMNITROPE (somatropin inj 5 mg/1.5 ml, 10 mg/1.5 ml) | Growth Hormone Deficiency, Short Stature, Growth Failure | 11/15/2023 |
| OPVEE (nalmefene hcl nasal spray 2.7 mg/0.1 ml (base equiv)) | Opioid Overdose | 12/1/2023 |
| PAXLOVID (nirmatrelvir tab 10 x 150 mg & ritonavir tab 10 x 100 mg pak, 20 x 150 mg & ritonavir tab 10 x 100 mg pak) | COVID-19 | 10/22/2023 |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Drug Tier Changes – Effective Jan. 1, 2024

The tier changes listed below apply to members on a managed drug list.

Balanced Drug List Tier Changes

| Drug ¹ | Condition | New Lower Tier |
|--|---|-------------------|
| amitriptyline hcl tab 75 mg | Depression | Preferred Generic |
| amoxicillin & k clavulanate for susp 400-57 mg/5 ml | Bacterial Infections | Preferred Generic |
| amphetamine-dextroamphetamine tab 5 mg | ADHD, Narcolepsy/Daytime Sleepiness | Preferred Generic |
| armodafinil tab 50 mg | Sleep Disorders | Preferred Generic |
| AUVI-Q (epinephrine solution auto-injector 0.1 mg/0.1 ml, 0.15 mg/0.15 ml, 0.3 mg/0.3 ml | Anaphylaxis, Severe Hypersensitivity Reactions | Preferred Brand |
| azithromycin for susp 200 mg/5 ml | Infections | Preferred Generic |
| baclofen tab 20 mg | Spasticity associated with Multiple Sclerosis and Spinal Cord Lesions | Preferred Generic |
| bisoprolol & hydrochlorothiazide tab 2.5-6.25 mg, 10-6.25 mg | Hypertension | Preferred Generic |
| bumetanide tab 0.5 mg | Edema, Volume Overload | Preferred Generic |
| bupropion hcl tab 100 mg | Depression | Preferred Generic |
| cefuroxime axetil tab 250 mg | Infections | Preferred Generic |
| cephalexin for susp 125 mg/5 ml | Infections | Preferred Generic |
| clotrimazole w/ betamethasone cream 1-0.05% | Fungal Infections | Preferred Generic |
| clozapine tab 25 mg | Schizophrenia, suicidal behavior in schizophrenia | Preferred Generic |
| cyproheptadine hcl syrup 2 mg/5 ml | Allergic Symptoms, Allergic Reactions | Preferred Generic |
| desogest-eth estrad & eth estrad tab 0.15-0.02/0.01 mg (21/5) | Contraception | Preferred Generic |
| diazepam oral soln 1 mg/ml | Alcohol withdrawal syndrome, anxiety, muscle spasm, spasticity, or rigidity, seizures | Preferred Generic |
| diltiazem hcl cap er 24 hr 120 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina | Preferred Generic |
| diltiazem hcl coated beads cap er 24 hr 240 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina | Preferred Generic |
| doxepin hcl cap 25 mg | Depression | Preferred Generic |
| doxycycline hyclate tab 20 mg | Acne, Infections | Preferred Generic |
| doxycycline monohydrate tab 50 mg | Acne, Infections | Preferred Generic |
| drospirenone-ethinyl estradiol tab 3-0.03 mg | Contraception | Preferred Generic |
| flurbiprofen tab 100 mg | Osteoarthritis, Rheumatoid Arthritis | Preferred Generic |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

^{*}Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Please note: If coverage of the member's medication is changed on their prescription drug list, the amount the member will pay for the same medication under this preventive drug benefit may also change.

Balanced Drug List Tier Changes

| Drug ¹ | Condition | New Lower Tier |
|---|---|-------------------|
| fluticasone propionate cream 0.05% | Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses | Preferred Generic |
| guanfacine hcl tab er 24 hr 1 mg, 2 mg, 3 mg, 4 mg (base equiv) | ADHD | Preferred Generic |
| HEMANGEOL (propranolol hcl oral soln 4.28 mg/ml) | Infantile Hemangioma | Preferred Brand |
| hydrocodone-acetaminophen tab 10-325 mg | Pain | Preferred Generic |
| hydrocortisone lotion 2.5% | Pruritus, Dermatoses | Preferred Generic |
| ketorolac tromethamine tab 10 mg | Pain | Preferred Generic |
| lactulose (encephalopathy) solution 10 gm/15 ml | Hepatic Encephalopathy | Preferred Generic |
| medroxyprogesterone acetate im susp prefilled syr 150 mg/ml | Contraception | Preferred Generic |
| methotrexate sodium tab 2.5 mg (base equiv) | Cancer, Rheumatoid Arthritis, Psoriasis, Polyarticular Juvenile Arthritis | Preferred Generic |
| methyldopa tab 500 mg | Hypertension | Preferred Generic |
| methylphenidate hcl tab 10 mg | ADHD, Narcolepsy | Preferred Generic |
| nitrofurantoin monohydrate macrocrystalline cap 100 mg | Cystitis | Preferred Generic |
| norgestrel & ethinyl estradiol tab 0.3 mg-30 mcg | Contraception | Preferred Generic |
| nystatin susp 100,000 unit/ml | Oral Candidiasis | Preferred Generic |
| olmesartan medoxomil-hydrochlorothiazide tab 40- 12.5 mg, 40-25 mg | Hypertension | Preferred Generic |
| ondansetron hcl oral soln 4 mg/5 ml | Nausea and Vomiting | Preferred Generic |
| oxcarbazepine tab 150 mg | Seizures | Preferred Generic |
| potassium phosphate monobasic tab 500 mg | To acidify the urine to lower urinary calcium; reduce odor and rash caused by ammonia in urine; to increase antibacterial activity of methenamine | Preferred Generic |
| prednisone tab therapy pack 10 mg (21) | Inflammatory Conditions | Preferred Generic |
| propranolol hcl oral soln 20 mg/5 ml | Angina, atrial fibrillation, essential tremor, hypertension, migraine, myocardial infarction, pheocrhomocytoma, hypertrophic subaortic stenosis | Preferred Generic |
| quetiapine fumarate tab er 24 hr 150 mg | Bipolar disorder, depression, schizophrenia | Preferred Generic |
| quetiapine fumarate tab sr 24 hr 150 mg | Bipolar disorder, depression, schizophrenia | Preferred Generic |
| quinidine sulfate tab 200 mg | Atrial Fib/Flutter, Ventricular arrhythmias | Preferred Generic |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Balanced Drug List Tier Changes

| Drug ¹ | Condition | New Lower Tier |
|---|--|-------------------|
| rizatriptan benzoate oral disintegrating tab 5 mg, 10 mg (base eq) | Migraine | Preferred Generic |
| solifenacin succinate tab 10 mg | Overactive Bladder | Preferred Generic |
| tamoxifen citrate tab 20 mg (base equivalent) | Breast cancer (treatment and risk reduction) | Preferred Generic |
| telmisartan tab 20 mg | Hypertension, cardiovascular risk reduction | Preferred Generic |
| testosterone cypionate im inj in oil 100 mg/ml | Primary hypogonadism, hypogonadotrophic hypogonadism | Preferred Generic |
| valsartan tab 320 mg | Heart failure, Hypertension, Cardiovascular risk reduction post- myocardial infarction | Preferred Generic |

Performance Drug List Tier Changes

| Drug ¹ | Condition | New Lower Tier |
|--|--|-------------------|
| amitriptyline hcl tab 75 mg | Depression | Preferred Generic |
| amoxicillin & k clavulanate for susp 400-57 mg/5 ml | Bacterial Infections | Preferred Generic |
| amphetamine-dextroamphetamine tab 5 mg | ADHD, Narcolepsy/Daytime Sleepiness | Preferred Generic |
| armodafinil tab 50 mg | Sleep Disorders | Preferred Generic |
| azithromycin for susp 200 mg/5 ml | Infections | Preferred Generic |
| baclofen tab 20 mg | Spasticity associated with Multiple Sclerosis and Spinal Cord Lesions | Preferred Generic |
| bisoprolol & hydrochlorothiazide tab 2.5-6.25 mg, 10-6.25 mg | Hypertension | Preferred Generic |
| bumetanide tab 0.5 mg | Edema, Volume Overload | Preferred Generic |
| bupropion hcl tab 100 mg | Depression | Preferred Generic |
| cefuroxime axetil tab 250 mg | Infections | Preferred Generic |
| cephalexin for susp 125 mg/5 ml | Infections | Preferred Generic |
| clotrimazole w/ betamethasone cream 1-0.05% | Fungal Infections | Preferred Generic |
| clozapine tab 25 mg | Schizophrenia, suicidal behavior in schizophrenia | Preferred Generic |
| cyproheptadine hcl syrup 2 mg/5 ml | Allergic Symptoms, Allergic Reactions | Preferred Generic |
| desogest-eth estrad & eth estrad tab 0.15-0.02/0.01 mg (21/5) | Contraception | Preferred Generic |
| diazepam oral soln 1 mg/ml | Alcohol withdrawal syndrome, anxiety, muscle spasm, spasticity, or rigidity, seizures | Preferred Generic |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

^{*}Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Please note: If coverage of the member's medication is changed on their prescription drug list, the amount the member will pay for the same medication under this preventive drug benefit may also change.

| Drug ¹ | Condition | New Lower Tier |
|---|--|-------------------|
| diltiazem hcl cap er 24 hr 120 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina | Preferred Generic |
| diltiazem hcl coated beads cap er 24 hr 240 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina | Preferred Generic |
| diltiazem hcl coated beads cap sr 24 hr 240 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina | Preferred Generic |
| doxepin hcl cap 25 mg | Depression | Preferred Generic |
| doxycycline hyclate tab 20 mg | Acne, Infections | Preferred Generic |
| doxycycline monohydrate tab 50 mg | Acne, Infections | Preferred Generic |
| drospirenone-ethinyl estradiol tab 3-0.03 mg | Contraception | Preferred Generic |
| flurbiprofen tab 100 mg | Osteoarthritis, Rheumatoid Arthritis | Preferred Generic |
| fluticasone propionate cream 0.05% | Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses | Preferred Generic |
| guanfacine hcl tab er 24 hr 1 mg, 2 mg, 3 mg, 4 mg (base equiv) | ADHD | Preferred Generic |
| hydrocodone-acetaminophen tab 10-325 mg | Pain | Preferred Generic |
| hydrocortisone lotion 2.5% | Pruritus, Dermatoses | Preferred Generic |
| ketorolac tromethamine tab 10 mg | Pain | Preferred Generic |
| lactulose (encephalopathy) solution 10 gm/15 ml | Hepatic Encephalopathy | Preferred Generic |
| LO LOESTRIN FE (norethin-eth estradiol-fe tab 1 mg-10 mcg (24)/10 mcg (2)) | Contraception | Preferred Brand |
| medroxyprogesterone acetate im susp prefilled syr 150 mg/ml | Contraception | Preferred Generic |
| methotrexate sodium tab 2.5 mg (base equiv) | Cancer, Rheumatoid Arthritis, Psoriasis, Polyarticular Juvenile Arthritis | Preferred Generic |
| methyldopa tab 500 mg | Hypertension | Preferred Generic |
| methylphenidate hcl tab 10 mg | ADHD, Narcolepsy | Preferred Generic |
| nitrofurantoin monohydrate macrocrystalline cap 100 mg | Cystitis | Preferred Generic |
| norgestrel & ethinyl estradiol tab 0.3 mg-30 mcg | Contraception | Preferred Generic |
| nystatin susp 100,000 unit/ml | Oral Candidiasis | Preferred Generic |
| olmesartan medoxomil-hydrochlorothiazide tab 40- 12.5 mg, 40-25 mg | Hypertension | Preferred Generic |
| ondansetron hcl oral soln 4 mg/5 ml | Nausea and Vomiting | Preferred Generic |
| oxcarbazepine tab 150 mg | Seizures | Preferred Generic |

Performance Drug List Tier Changes

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

| Drug ¹ | Condition | New Lower Tier |
|---|--|-------------------|
| potassium phosphate monobasic tab 500 mg | To acidify the urine to lower urinary calcium; reduce odor and rash caused by ammonia in urine; to increase antibacterial activity of methenamine | Preferred Generic |
| prednisone tab therapy pack 10 mg (21) | Inflammatory Conditions | Preferred Generic |
| propranolol hcl oral soln 20 mg/5 ml | Angina, atrial fibrillation, essential tremor, hypertension, migraine, myocardial infarction, pheocrhomocytoma, hypertrophic subaortic stenosis | Preferred Generic |
| quetiapine fumarate tab er 24 hr 150 mg | Bipolar disorder, depression, schizophrenia | Preferred Generic |
| quetiapine fumarate tab sr 24 hr 150 mg | Bipolar disorder, depression, schizophrenia | Preferred Generic |
| quinidine sulfate tab 200 mg | Atrial Fib/Flutter, Ventricular arrhythmias | Preferred Generic |
| rizatriptan benzoate oral disintegrating tab 5 mg, 10 mg (base eq) | Migraine | Preferred Generic |
| solifenacin succinate tab 10 mg | Overactive Bladder | Preferred Generic |
| tamoxifen citrate tab 20 mg (base equivalent) | Breast cancer (treatment and risk reduction) | Preferred Generic |
| telmisartan tab 20 mg | Hypertension, cardiovascular risk reduction | Preferred Generic |
| testosterone cypionate im inj in oil 100 mg/ml | Primary hypogonadism, hypogonadotrophic hypogonadism | Preferred Generic |
| valsartan tab 320 mg | Heart failure, Hypertension, Cardiovascular risk reduction post-myocardial infarction | Preferred Generic |

Performance Drug List Tier Changes

Performance Select Drug List Tier Changes

| Drug ¹ | Condition | New Lower Tier |
|---|---|-------------------|
| amitriptyline hcl tab 75 mg | Depression | Preferred Generic |
| amoxicillin & k clavulanate for susp 400-57 mg/ ml | Bacterial Infections | Preferred Generic |
| amphetamine-dextroamphetamine tab 5 mg | ADHD, Narcolepsy/Daytime Sleepiness | Preferred Generic |
| armodafinil tab 50 mg | Sleep Disorders | Preferred Generic |
| AUVI-Q (epinephrine solution auto-injector 0.15 mg/0.15 ml (1:1000), 0.3 mg/0.3ml (1:1000) | Anaphylaxis, Severe Hypersensitivity Reactions | Preferred Brand |
| azithromycin for susp 200 mg/5 ml | Infections | Preferred Generic |
| baclofen tab 20 mg | Spasticity associated with Multiple Sclerosis and Spinal Cord Lesions | Preferred Generic |
| bisoprolol & hydrochlorothiazide tab 2.5-6.25 mg, 10-6.25 mg | Hypertension | Preferred Generic |
| bumetanide tab 0.5 mg | Edema, Volume Overload | Preferred Generic |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

^{*}Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Please note: If coverage of the member's medication is changed on their prescription drug list, the amount the member will pay for the same medication under this preventive drug benefit may also change.

Performance Select Drug List Tier Changes

| Drug ¹ | Condition | New Lower Tier |
|--|--|-------------------|
| bupropion hcl tab 100 mg | Depression | Preferred Generic |
| cefuroxime axetil tab 250 mg | Infections | Preferred Generic |
| cephalexin for susp 125 mg/5 ml | Infections | Preferred Generic |
| clotrimazole w/ betamethasone cream 1-0.05% | Fungal Infections | Preferred Generic |
| clozapine tab 25 mg | Schizophrenia, suicidal behavior in schizophrenia | Preferred Generic |
| cyproheptadine hcl syrup 2 mg/5 ml | Allergic Symptoms, Allergic Reactions | Preferred Generic |
| desogest-eth estrad & eth estrad tab 0.15- 0.02/0.01 mg (21/5) | Contraception | Preferred Generic |
| diazepam oral soln 1 mg/ml | Alcohol withdrawal syndrome, anxiety, muscle spasm, spasticity, or rigidity, seizures | Preferred Generic |
| diltiazem hcl cap er 24 hr 120 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina | Preferred Generic |
| diltiazem hcl coated beads cap er 24 hr 240 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina | Preferred Generic |
| diltiazem hcl coated beads cap sr 24 hr 240 mg | Hypertension, Chronic Stable Angina, Vasospastic Angina | Preferred Generic |
| doxepin hcl cap 25 mg | Depression | Preferred Generic |
| doxycycline hyclate tab 20 mg | Acne, Infections | Preferred Generic |
| doxycycline monohydrate tab 50 mg | Acne, Infections | Preferred Generic |
| drospirenone-ethinyl estradiol tab 3-0.03 mg | Contraception | Preferred Generic |
| flurbiprofen tab 100 mg | Osteoarthritis, Rheumatoid Arthritis | Preferred Generic |
| fluticasone propionate cream 0.05% | Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses | Preferred Generic |
| guanfacine hcl tab er 24 hr 1 mg, 2 mg, 3 mg, 4 mg (base equiv) | ADHD | Preferred Generic |
| HEMANGEOL (propranolol hcl oral soln 4.28 mg/ml) | Infantile Hemangioma | Preferred Brand |
| hydrocodone-acetaminophen tab 10-325 mg | Pain | Preferred Generic |
| hydrocortisone lotion 2.5% | Pruritus, Dermatoses | Preferred Generic |
| ketorolac tromethamine tab 10 mg | Pain | Preferred Generic |
| lactulose (encephalopathy) solution 10 gm/15 ml | Hepatic Encephalopathy | Preferred Generic |
| medroxyprogesterone acetate im susp prefilled syr 150 mg/ml | Contraception | Preferred Generic |
| methotrexate sodium tab 2.5 mg (base equiv) | Cancer, Rheumatoid Arthritis, Psoriasis, Polyarticular Juvenile Arthritis | Preferred Generic |
| methyldopa tab 500 mg | Hypertension | Preferred Generic |
| | | |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

| Drug ¹ | Condition | New Lower Tier |
|---|--|-------------------|
| methylphenidate hcl tab 10 mg | ADHD, Narcolepsy | Preferred Generic |
| nitrofurantoin monohydrate macrocrystalline cap 100 mg | Cystitis | Preferred Generic |
| norgestrel & ethinyl estradiol tab 0.3 mg-30 mcg | Contraception | Preferred Generic |
| nystatin susp 100,000 unit/ml | Oral Candidiasis | Preferred Generic |
| olmesartan medoxomil-hydrochlorothiazide tab 40- 12.5 mg, 40-25 mg | Hypertension | Preferred Generic |
| ondansetron hcl oral soln 4 mg/5 ml | Nausea and Vomiting | Preferred Generic |
| oxcarbazepine tab 150 mg | Seizures | Preferred Generic |
| potassium phosphate monobasic tab 500 mg | To acidify the urine to lower urinary calcium; reduce odor and rash caused by ammonia in urine; to increase antibacterial activity of methenamine | Preferred Generic |
| prednisone tab therapy pack 10 mg (21) | Inflammatory Conditions | Preferred Generic |
| propranolol hcl oral soln 20 mg/5 ml | Angina, atrial fibrillation, essential tremor, hypertension, migraine, myocardial infarction, pheochromocytoma, hypertrophic subaortic stenosis | Preferred Generic |
| quetiapine fumarate tab er 24 hr 150 mg | Bipolar disorder, depression, schizophrenia | Preferred Generic |
| quetiapine fumarate tab sr 24 hr 150 mg | Bipolar disorder, depression, schizophrenia | Preferred Generic |
| quinidine sulfate tab 200 mg | Atrial Fib/Flutter, Ventricular arrhythmias | Preferred Generic |
| rizatriptan benzoate oral disintegrating tab 5 mg, 10 mg (base eq) | Migraine | Preferred Generic |
| solifenacin succinate tab 10 mg | Overactive Bladder | Preferred Generic |
| tamoxifen citrate tab 20 mg (base equivalent) | Breast cancer (treatment and risk reduction) | Preferred Generic |
| telmisartan tab 20 mg | Hypertension, cardiovascular risk reduction | Preferred Generic |
| testosterone cypionate im inj in oil 100 mg/ml | Primary hypogonadism, hypogonadotrophic hypogonadism | Preferred Generic |
| valsartan tab 320 mg | Heart failure, Hypertension, Cardiovascular risk reduction post-myocardial infarction | Preferred Generic |

Performance Select Drug List Tier Changes

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Other Drug List Tier Changes

Most tier changes become effective quarterly, however, some drugs are moved to a new tier as part of formulary maintenance or re-evaluated during the quarter. Those drugs are listed below with their addition date.

| Drug ¹ | Condition | Date Added | New Lower Tier |
|-------------------------------------|---------------------------|------------|-----------------------|
| dexamethasone tab 0.5 mg, | Inflammatory Conditions | 11/5/2023 | Preferred Generic |
| 0.75 mg, | | | |
| dexamethasone tab 1 mg | Inflammatory Conditions | 11/5/2023 | Non-Preferred Generic |
| diazepam rectal gel delivery system | Acute Repetitive Seizures | 10/29/2023 | Non-Preferred Generic |
| 10 mg, 20 mg | | | |
| nortriptyline hcl soln 10 mg/5 ml | Depression | 10/29/2023 | Non-Preferred Generic |
| phenytoin sodium extended cap | Seizures | 10/8/2023 | Non-Preferred Generic |
| 200 mg | | | |
| sevelamer hcl tab 400 mg | Hyperphosphatemia | 11/5/2023 | Non-Preferred Generic |
| SPIRIVA HANDIHALER (tiotropium | Chronic Obstructive | 10/15/2023 | Non-Preferred Generic |
| bromide monohydrate inhal cap | Pulmonary Disease (COPD) | | |
| 18 mcg (base equivalent)) | | | |

Balanced Drug List Tier Changes

Performance Drug List Tier Changes

| Drug ¹ | Condition | Date Added | New Lower Tier |
|---|---------------------------|------------|-----------------------|
| dexamethasone tab 0.5 mg, 0.75 mg | Inflammatory Conditions | 11/5/2023 | Preferred Generic |
| dexamethasone tab 1 mg | Inflammatory Conditions | 11/5/2023 | Non-Preferred Generic |
| diazepam rectal gel delivery system 10 mg, 20 mg | Acute Repetitive Seizures | 10/29/2023 | Non-Preferred Generic |
| nortriptyline hcl soln 10 mg/5 ml | Depression | 10/29/2023 | Non-Preferred Generic |
| phenytoin sodium extended cap 200 mg | Seizures | 10/8/2023 | Non-Preferred Generic |
| sevelamer hcl tab 400 mg | Hyperphosphatemia | 11/5/2023 | Non-Preferred Generic |

Performance Select Drug List Tier Changes

| Drug ¹ | Condition | Date Added | New Lower Tier |
|--|--|------------|-----------------------|
| dexamethasone tab 0.5 mg, 0.75 mg | Inflammatory Conditions | 11/5/2023 | Preferred Generic |
| dexamethasone tab 1 mg | Inflammatory Conditions | 11/5/2023 | Non-Preferred Generic |
| diazepam rectal gel delivery system 10 mg, 20 mg | Acute Repetitive Seizures | 10/29/2023 | Non-Preferred Generic |
| nortriptyline hcl soln 10 mg/5 ml | Depression | 10/29/2023 | Non-Preferred Generic |
| phenytoin sodium extended cap 200 mg | Seizures | 10/8/2023 | Non-Preferred Generic |
| sevelamer hcl tab 400 mg | Hyperphosphatemia | 11/5/2023 | Non-Preferred Generic |
| SPIRIVA HANDIHALER (tiotropium bromide monohydrate inhal cap 18 mcg (base equivalent)) | Chronic Obstructive Pulmonary Disease (COPD) | 10/15/2023 | Non-Preferred Generic |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Utilization Management Program Changes

Utilization Management programs are implemented to regularly review the appropriateness of medications within drugtherapy programs, and as a result, may adjust dispensing limits, prior authorization or step-therapy requirements. The following drug programs reflect those changes.

Dispensing Limit Changes

BCBSMT's prescription drug benefit program includes coverage limits on certain medications and drug categories. Dispensing limits, or quantity limits (QLs), are based on U.S. Food and Drug Administration (FDA) approved dosage regimens and product labeling. **New dispensing limits and effective dates are listed on the chart below.**

Balanced, Performance, and Performance Select, Basic, Basic Multi-Tier, Basic Annual, Basic Multi-Tier Annual, Enhanced, Enhanced Annual, Enhanced Annual Multi-Tier, Health Information Marketplace (HIM) Drug Lists

| Medication(s) ¹ | Former Dispensing Limit | New Dispensing Limit | Effective Date |
|--|-------------------------|-----------------------|----------------|
| Prevymis (letermovir) 240 mg tab, 480 mg tab | 112 tabs per 180 days | 200 tabs per 365 days | 12/1/2023 |
| Vanos 0.1% cream | 120 grams per 180 days | 120 grams per 90 days | 1/1/2024 |

Standard Utilization Management Program Updates

The prior authorization (PA) programs for standard pharmacy benefit plans correlate to a member's drug list. Not all standard PA programs may apply, based on the member's current drug list. A list of PA programs per drug list is posted on the member pharmacy programs section of <u>bcbsmt.com</u>. View the most up-to-date drug list and list of drug dispensing limits on <u>bcbsmt.com</u>.

If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their member ID card. Members may also visit bcbsmt.com and log in to Blue Access for MembersSM (BAMSM) or MyPrime.com for a variety of online resources.

Program Removals

The following standard utilization management programs were updated to remove target drugs on the dates indicated below.

- Alternative Dosage Form PAQL: removed Digoxin oral soln 0.05 mg/mL and spironolactone susp 25 mg/mL from this program effective Jan. 1, 2024.
- **Oral Tetracycline Derivatives PA:** removed Doxycycline Monohydrate 150 mg tab from this program effective Dec. 15, 2023.
- **Supplemental Therapeutic Alternatives** removed Auvi-Q and Winlevi from this program effective Jan. 1, 2024. Winlevi has moved to the Winlevi PA, effective Jan. 1, 2024.
- **Therapeutic Alternatives PAQL:** removed Cardizem CD, Dexamethasone therapy Pak, Prolate and Vanos, effective Jan. 1, 2024.

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

^{*}Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Please note: If coverage of the member's medication is changed on their prescription drug list, the amount the member will pay for the same medication under this preventive drug benefit may also change.

Program Retirements

The following standard utilization management programs have been retired on the dates indicated below.

- Amantadine ER PAQL program was retired Nov. 15, 2023. This program included the following drugs: Gocovri (Amantadine HCL) ER cap 24 hr 68.5 mg, 137 mg (base), Osmolex ER (Amantadine HCL) 24 hr 129 mg tab, 193 mg tab, 258 mg tab, and Osmolex ER (Amantadine HCL) 24 hr Pak 129 mg & 193 mg (322 mg dose)
- Amylin Analogues QL program was retired Nov. 15, 2023. This program included the following drugs: Symlinpen (pramlintide acetate) 120 and Symlinpen (pramlintide acetate) 60.
- Natpara PAQL was retired effective Nov. 15, 2023. This program included the following drugs: Natpara parathyroid hormone (recombinant) for Inj cartridge 25 mcg, 50 mcg, 75 mcg, 100 mcg.
- Nuvigil, Provigil PAQL was retired effective Nov. 15, 2023. This program included the following drugs: NUVIGIL (armodafinil) tab 50 mg, 150 mg, 200 mg, 250 mg and PROVIGIL (modafinil) tab 100 mg.
- Rho Kinase Inhibitors STQL was retired effective Nov. 15, 2023. This program included the following drugs Rhopressa (Netarsudil dimesylate) opth soln 0.02% and Rocklatan (Netasurdil dimesylate-latanoprost) opthl soln 0.02-0.005%.

Change in Benefit Coverage for Select High-Cost Products

Several high-cost products with available lower cost alternatives will be excluded on the pharmacy benefit for select drug lists. This change impacts BCBSMT members who have prescription-drug benefits administered by Prime Therapeutics[†]. This change is part of an ongoing effort to make sure our members and employer groups have access to safe, cost-effective medications.

Please note: Members were not notified of this change because either there is no utilization, or the pharmacist can easily fill a member's prescription with the equivalent without needing a new prescription from the doctor. The following drugs are excluded on select drug lists.

| Product(s) No Longer Covered ¹ | Condition | Covered Alternative(s) ^{1, 2} |
|---|-----------|--|
| Diclofenac Potassium 25 mg Tablets | | Diclofenac Potassium 50 mg, meloxicam, ibuprofen, naproxen |

¹*Third-party brand names are the property of their respective owner.*

²This list is not all inclusive. Other medicines may be available in this drug class.

³Coverage of medications is still subject to the limits, exclusions and out-of-pocket requirements based on the member's plan.

*Not all plans cover these products. Plans must opt-in to cover this product. Check your benefits packet for more details.

Pharmacy Benefits Updates

BCBSMT Offers LifeScan as Preferred Option for Glucose Management

New for Members with Diabetes: The LifeScan[®] One Touch test strips and supplies have been added as preferred options for BCBSMT members with diabetes effective Jan. 1, 2024. LifeScan products include the OneTouch family of meters, such as the OneTouch Verio Reflect[®], Verio Flex[®], Ultra Plus Flex[™], and Ultra 2[®] test strips and supplies.

All preferred diabetic glucose-monitoring devices and supplies are available to members with Prime Therapeutics as their pharmacy benefit manager. Members can use a coupon to receive a free OneTouch meter.

- Contour and Contour Next test strips remain preferred options for managing diabetes. Members can use a coupon to obtain the Contour Next Gen and Contour Next EZ meters at no cost, as well.
- LifeScan's OneTouch test strips have been removed from the Glucose Test Strip STQL effective Jan. 1, 2024.

Note: The member flier contains a coupon for members to obtain a free blood glucose monitor.

Appropriate Use of Opioids Program to be Retired January 2024

What's new: The Appropriate Use of Opioids program will be retired effective January 1, 2024. However, BCBSMT will continue to promote safe and effective use of prescription opioids through an approach that more closely aligns with the Center for Disease Control's 2022 Guidelines for Prescribing Opioids for Pain, which emphasize flexibility and individualized care.

New Approach: BCBSMT's new approach will eliminate hard edits – or benefit rejections at the pharmacy counter – and instead be updated to soft edits, which will allow the pharmacy or provider to determine whether to dispense.

The soft edits are in place to alert the pharmacy if: an opioid naïve member has an opioid prescription that exceeds seven days; or, if a member has exceeded dosage limits and has filled overlapping opioid prescriptions at two or more pharmacies and from two or more providers.

A member is considered opioid naïve if they have not filled an opioid prescription within the past 60 days, based on pharmacy claims data. Examples of medications targeted by these new standards are opioid agonists like codeine, oxycodone, hydromorphone, morphine, and opioid combination products like oxycodone/acetaminophen and hydrocodone/acetaminophen.

Also new on Jan. 1, 2024, is the Opioids Extended Release Prior Authorization Quantity Limits program with Oxycontin as the lone target. Other opioid quantity limits which existed under AUO will continue under the new Opioids ER PAQL.

Reminder: BCBSMT's Updated Approach to Managing GLP-1 Agonist Medications

Blue Cross and Blue Shield of MT is committed to providing its members access to safe, appropriate, and cost-effective health care within their plan benefits. To ensure the appropriate use of GLP-1s as indicated for diabetes, we are making it easier for providers to bypass our prior authorization (PA) process for some of our members with diabetes. For more information, review the full article on bcbsmt.com.

[†]Prime Therapeutics LLC is a pharmacy benefit management company. BCBSMT contracts with Prime to provide pharmacy benefit management and related other services. BCBSMT, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime. MyPrime.com is an online resource offered by Prime Therapeutics.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.